These approaches include the use of insulin sensitizer agents or intranasal insulin to restore insulin signaling in AD, as well as antidiabetic drugs such as Metformin and Glucagon-like peptide-1 receptor (GLP-1R) agonists. The gene discussed is INS; the disease is Alzheimer disease.